ACRV Stock Summary and Trading Ideas (Acrivon Therapeutics | NASDAQ:ACRV)

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Acrivon Therapeutics trades on the NASDAQ stock market under the symbol ACRV.

As of November 6, 2026, ACRV stock price climbed to $1.61 with 352,408 million shares trading.

ACRV has a beta of 1.70, meaning it tends to be more sensitive to market movements. ACRV has a correlation of 0.07 to the broad based SPY ETF.

ACRV has a market cap of $68.99 million. This is considered a Micro Cap stock.

Last quarter Acrivon Therapeutics reported $0 in Revenue and -$.43 earnings per share. This fell short of revenue expectation by $-464,000 and exceeded earnings estimates by $.07.

In the last 3 years, ACRV traded as high as $11.90 and as low as $1.05.

The top ETF exchange traded funds that ACRV belongs to (by Net Assets): VTI, VXF, IWC, BUSM, DXUV.

ACRV has underperformed the market in the last year with a price return of -20.7% while the SPY ETF gained +9.6%. However, in the short term, ACRV had mixed performance relative to the market. It has outperformed in the last 3 months, returning -1.8% vs -4.2% return in SPY. But in the last 2 weeks, ACRV shares have been beat by the market, returning -8.5% compared to an SPY return of -3.8%.

ACRV support price is $1.49 and resistance is $1.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRV shares will trade within this expected range on the day.